Nikhil I. Khushalani, MD, of Moffitt Cancer Center, discusses the diagnosis and prognosis of patients with locally advanced cutaneous squamous cell carcinoma.
Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.
1. Pooled overall survival and progression-free survival HR were found to be 0.95 and 0.88 for nivolumab/ipilimumab vs. nivolumab. 2. Pooled OR for grade 3-4 adverse events was found to be 1.84 for the combination compared to monotherapy Evidence Rating Level: 1 (Excellent) Study Rundown: Nivolumab/ipilimumab combination therapy has demonstrated improved progression-free survival (PFS) and